For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/primary-care-questions-on-moderate-to-severe-asthma-9617

Summary
Two experts from distinct clinical backgrounds – a primary care physician and a pulmonology PA – answer the top 5 questions primary care clinicians have about moderate-to-severe asthma. These questions come from clinician learners at Conversations in Primary Care (CPC) and Emerging Challenges and Clinical Updates in Primary Care (ECCU) live-virtual symposia from May through August, 2024.

In just 15 minutes, this podcast/webcast covers the latest on:

• New inhaler options: Albuterol/budesonide and smart therapy alternatives
• Montelukast: Weighing benefits against risks and boxed warnings
• Biomarkers: What to test and how to use the results to guide referrals
• Biologics: When to consider them and how to co-manage with specialists
• Practical tips: Best practices for primary care clinicians in everyday asthma management

Learning Objectives
Upon completion of this activity, learners should be able to:

• Evaluate patients with asthma to identify those with inflammatory phenotypes who are more likely to have exacerbations and severe disease
• Escalate care for patients with moderate-to-severe asthma uncontrolled on ICS-LABA

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0.25 hours of pharmacology.

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.